Vapotherm

OverviewSuggest Edit

Vapotherm develops and manufactures comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. The Company is an inventor of  inventor of Hi-VNI® Technology.

TypePublic
Founded1999
HQExeter, NH, USMap
Websitevapotherm.com
Employee Ratings3.6More
View Jobs (33)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)279(+2%)
Job Openings33
Revenue (FY, 2020)$125.7 M(+162%)
Share Price (Sept 2021)$29.4(+4%)
Cybersecurity ratingBMore

Key People/Management at Vapotherm

Joseph Army

Joseph Army

President & Chief Executive Officer
John Landry

John Landry

Vice President & Chief Financial Officer
Lindsay Becker

Lindsay Becker

Vice President, Human Resources
David Blouin

David Blouin

Vice President, U.S. Sales
John Coolidge

John Coolidge

Vice President, Operations
Jill Dooling

Jill Dooling

Vice President, Strategic Accounts
Show more

Vapotherm Office Locations

Vapotherm has an office in Exeter
Exeter, NH, US (HQ)
100 Domain Dr
Show all (1)

Vapotherm Financials and Metrics

Vapotherm Revenue

Embed Graph
View revenue for all periods
Vapotherm's revenue was reported to be $125.73 m in FY, 2020
USD

Revenue (Q1, 2021)

32.3m

Gross profit (Q1, 2021)

17.2m

Gross profit margin (Q1, 2021), %

53.1%

Net income (Q1, 2021)

(10.4m)

EBIT (Q1, 2021)

(9.7m)

Market capitalization (8-Sept-2021)

760.8m

Closing stock price (8-Sept-2021)

29.4

Cash (31-Mar-2021)

93.8m

EV

671.8m
Vapotherm's current market capitalization is $760.8 m.
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Revenue

30.1m35.6m48.1m125.7m

Revenue growth, %

18%

Cost of goods sold

20.2m22.4m26.8m62.7m

Gross profit

9.9m13.2m21.3m63.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

9.1m8.2m7.9m10.7m10.6m9.4m12.3m12.0m10.8m19.1m35.2m30.6m32.3m

Cost of goods sold

5.5m4.8m5.1m6.5m6.5m5.8m7.1m6.5m6.0m9.9m17.5m15.0m15.1m

Gross profit

3.6m3.4m2.8m4.2m4.1m3.6m5.2m5.5m4.8m9.2m17.6m15.5m17.2m

Gross profit Margin, %

40%41%35%40%39%39%42%46%44%48%50%51%53%
show all
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Cash

5.8m26.5m71.7m113.7m

Accounts Receivable

5.9m7.0m8.2m23.5m

Prepaid Expenses

1.8m2.3m4.1m5.0m

Inventories

8.2m11.5m9.1m19.9m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

56.7m46.1m83.5m60.4m148.3m139.0m93.8m

Accounts Receivable

6.7m7.3m6.8m11.9m16.5m10.9m13.7m

Prepaid Expenses

2.5m2.3m2.1m4.0m4.5m4.9m6.5m

Inventories

12.4m11.2m10.8m9.1m18.6m25.0m26.9m
show all
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(31.0m)(23.1m)(51.1m)(51.5m)

Depreciation and Amortization

1.5m1.3m3.1m4.8m

Inventories

(3.3m)374.0k5.1m(10.2m)

Accounts Payable

285.0k996.0k98.0k1.5m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(22.0m)(29.6m)(13.0m)(25.8m)(38.6m)(13.8m)(21.9m)(34.3m)(10.4m)

Depreciation and Amortization

1.1m1.6m621.0k1.4m2.2m1.1m2.1m3.4m1.6m

Inventories

(3.1m)(1.1m)1.8m3.0m3.4m(12.0k)(9.2m)(15.5m)(7.0m)

Accounts Payable

(127.0k)(336.0k)(1.7m)(1.6m)(1.6m)1.3m3.4m2.8m870.0k
show all
USDFY, 2016

Financial Leverage

-0.3 x
Show all financial metrics

Vapotherm Operating Metrics

Q3, 2018

Hospitals Engaged

1.2 k
Show all operating metrics

Vapotherm Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

Learn more about our premium products
SecurityScorecard logo

Vapotherm Online and Social Media Presence

Vapotherm's Trends

Embed Graph

Vapotherm Blogs

September 17, 2021

Children’s Hospital Respiratory Department Operations

Garry Kauffman, RRT FAARC MPA FACHE, former AARC President, interviews Dave Crotwell, Respiratory Director for a tertiary Children’s Hospital in the Northwest to understand operational differences in a Children’s Hospital to Adult Hospital’s operations, specifically, as it relates to reimbursement, …
August 09, 2021

Respiratory Department Directors Discuss Productivity

John Walsh, Vapotherm VP of Clinical, sits down with Ed Garcia and Jonathan Butler, two current and longtime Respiratory Department Directors, to discuss Respiratory Department Productivity.   Ed and Jonathan provide overviews of their current productivity systems and how they work with their leader…
June 30, 2021

Safe Patient Care with Vapotherm High Velocity Therapy

Whether on the general care floor, in the emergency room, or the ICU, Vapotherm devices are designed with patient safety in mind. There are inherent risks in using any medical device on sick patients. Here are the ways in which we strive to give you confidence that you’re providing your respiratory …
May 14, 2021

AARC Safe and Effective Staffing Guide Recognizes High Velocity Therapy as NIV

The AARC released their Safe and Effective Staffing Guide (previous known as the AARC Uniform Reporting Manual (URM)), the association’s official productivity guide with time standards for most Respiratory Care Department procedures. The time standards are based on 2020 survey results from hundreds …
April 16, 2021

New Analysis Shows that Preterm Babies Can Be Effectively Stabilized in Delivery Room Using Vapotherm® as Primary Respiratory Support

In February 2021, Siva and Reynolds published the results of a retrospective, single center, observational cohort study in Acta Paediatrica titled “Stabilisation of the preterm infant in the delivery room using nasal high flow: A 5—year retrospective analysis.” The analysis examined the clinical out…
February 23, 2021

New Study Adds Evidence for Use of Vapotherm® High Velocity Therapy as First-Line Support on Severely Hypercapnic COPD Patients

Vapotherm high velocity therapy is an attractive alternative to traditional noninvasive positive pressure ventilation (NiPPV) for respiratory distress. This approach—which is a form of Mask-Free NIV®—redefines the notion that ventilatory support requires a mask-and-pressure-based mechanism of action…
Show more

 Vapotherm Frequently Asked Questions

  • When was Vapotherm founded?

    Vapotherm was founded in 1999.

  • Who are Vapotherm key executives?

    Vapotherm's key executives are Joseph Army, John Landry and Lindsay Becker.

  • How many employees does Vapotherm have?

    Vapotherm has 279 employees.

  • What is Vapotherm revenue?

    Latest Vapotherm annual revenue is $125.7 m.

  • What is Vapotherm revenue per employee?

    Latest Vapotherm revenue per employee is $450.7 k.

  • Who are Vapotherm competitors?

    Competitors of Vapotherm include ALung Technologies, Getinge and Air-Tite Products.

  • Where is Vapotherm headquarters?

    Vapotherm headquarters is located at 100 Domain Dr, Exeter.

  • Where are Vapotherm offices?

    Vapotherm has an office in Exeter.

  • How many offices does Vapotherm have?

    Vapotherm has 1 office.